سعر اليمتا 100مجم باودر فيال 2023

Pemetrexed 100 mg lyophilised powder in a single-dose vial for intravenous infusion (Eli Lilly), an antifolate antineoplastic used for non-squamous non-small cell lung cancer and malignant pleural mesothelioma.

• Initial treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, in combination with pembrolizumab and platinum chemotherapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Initial treatment of locally advanced or metastatic non-squamous NSCLC, in combination with cisplatinPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Maintenance treatment of locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥20%) as a single agent: fatigue, nausea and anorexia.International label, same product · DailyMed (U.S. National Library of Medicine)
• Most common adverse reactions (≥20%) with cisplatin: vomiting, neutropenia, anaemia, stomatitis/pharyngitis, thrombocytopenia and constipation.International label, same product · DailyMed (U.S. National Library of Medicine)

• History of severe hypersensitivity reaction to pemetrexed.International label, same product · DailyMed (U.S. National Library of Medicine)

• Myelosuppression, which can be severe and fatal; reduce risk with folic acid and vitamin B12 supplementation; withhold or reduce dose for severe myelosuppression.International label, same product · DailyMed (U.S. National Library of Medicine)
• Renal failure, including fatal cases; do not administer when creatinine clearance is <45 mL/min.International label, same product · DailyMed (U.S. National Library of Medicine)
• Serious bullous and exfoliative skin toxicity, including Stevens-Johnson syndrome and toxic epidermal necrolysis; permanently discontinue for severe or life-threatening reactions.International label, same product · DailyMed (U.S. National Library of Medicine)

• IbuprofenIbuprofen increases pemetrexed exposure (AUC). In patients with creatinine clearance 45-79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days after pemetrexed; if co-administration cannot be avoided, monitor more frequently for myelosuppression, renal and gastrointestinal toxicity.DailyMed (U.S. National Library of Medicine)

• Based on animal data and its mechanism of action, pemetrexed can cause fetal harm when administered to a pregnant woman; it was teratogenic in mice. Advise pregnant women of the potential risk to a fetus.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; because of the potential for serious adverse reactions in breastfed infants, advise not to breastfeed during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Pemetrexed: Folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication; inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT).